B. O'Connor (London, United Kingdom), A. Tattersfield (Nottingham, United Kingdom)
Efficacy of formoterol 12μg dry powder capsules in 6,155 asthmatic patients poorly controlled with salmeterol or on-demand salbutamol (EFORA study)
C. Brambilla, V. Le Gros, I. Bourdeix (Grenoble, France)
|  |
Efficacy and safety of montelukast sodium on adult bronchial asthma in a multicentre comparative double-blind clinical study with pranlukast hydrate
T. Miyamoto, S. Makino, S. Kitamura, K. Ito, J. Kabe, K. Mano, S. Nakajima, M. Yamakido, H. Yasuhara (Tokyo, Japan)
| |
Effects of 3-yr immunotherapy with standardised extracts of house dust mite in allergic asthmatic subjects receiving appropriate drug treatment
P. Maestrelli, L. Zanolla, P. Puccinelli, M. Pozzan, L. M. Fabbri (Verona, Milan, Italy)
| |
Theophylline drip infusion reduces peripheral blood eosinophil counts and ECP (eosinophil cationic protein) level on acute exacerbation of asthma
M. Kato, Y. Goto, H. Sakamoto, K. Okada (Kaizuka, Japan)
| |
Six months treatment with salmeterol or ipratropium bromide improves effort tolerance and reduces dyspnoea but does not have any effect on lung function in COPD
T. Pitsch, A. Krzywiecki, B. Rogala (Zabrze, Poland)
| |
Omalizumab, an anti-immunoglobin E antibody, is not associated with an increased risk of immunological reactions
S. G. O. Johansson, N. Gupta, A. van As (Stockholm, Sweden; East Hanover, United States Of America)
| |
Pharmacokinetic characteristics of roflumilast administered in gradually increasing doses of 500μg to 1000μg are dose-linear in healthy subjects
A. Manegold, B. Hauns, M. David, K. Zech, T. D. Bethke, W. Wurst (Konstanz, Germany)
| |
Patients with severe renal impairment do not require dose adjustment of roflumilast
A. Drollmann, M. Hartmann, K. Zech, M. David, C. Weimar, T. D. Bethke (Konstanz, Germany)
| |
Pharmacokinetics of roflumilast and its active metabolite roflumilast-N-oxide in middle aged and young subjects
A. Manegold, A. Huennemayer, K. Zech, B. Hauns, M. David, T. D. Bethke, W. Wurst (Konstanz, Germany)
| |
Pharmacokinetics of 14C-ciclesonide after oral and intravenous administration in healthy subjects
R. Nave, T. D. Bethke, S. P. van Marle, K. Zech (Konstanz, Germany; Zuidlaren, The Netherlands)
| |
High lung deposition of ciclesonide in 2D- and 3D-imaging
T. D. Bethke, R. J. Boudreau, B. E. Hasselquist, P. Davidson, C. L. Leach, A. Drollmann, B. Hauns, W. Wurst (Konstanz, Germany; Minneapolis, St. Paul, United States Of America)
| |
Pharmacokinetic characteristics of roflumilast and its active metabolite roflumilast-N-oxide are not affected by food intake
A. Drollmann, A. Huennemayer, M. Hartmann, B. Hauns, K. Zech, T. D. Bethke, W. Wurst (Konstanz, Germany)
| |
Bioequivalence of two ciclesonide dosing regimen (4 puffs of 200μg vs. 16 puffs of 50μg using an MDI)
T. D. Bethke, A. Drollmann, B. Hauns, R. Nave, K. Zech, V. W. Steinijans, W. Wurst (Konstanz, Germany)
| |
Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects
R. Nave, T. D. Bethke, M. Seiberling, V. W. Steinijans, K. Zech (Konstanz, Freiburg, Germany)
| |
Six month treatment with formoterol - efficacy and side effects
A. D. Barela, J. Wronska, A. Safianowska, K. Tyminska, R. Chazan (Warsaw, Poland)
| |
Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction
E. M. van Schalkwyk, K. van Heerden, D. Bredenbröker, S. Leichtl, W. Wurst, L. Venter, P. G. Bardin (Tygerberg, Rivonia, South Africa; Konstanz, Germany; Melbourne, Australia)
| |
Short-acting beta-agonist (SABA) and airway inflammation: dynamic negative interaction
J. M. Wraight, A. D. Smith, J. O. Cowan, E. M. Flannery, G. P. Herbison, D. R. Taylor (Dunedin, New Zealand)
| |
Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients
C. Sevinc, E. Ceylan, S. Sahbaz, F. Fidan, A. Hayretdag, O. Kilinc, O. Itil, A. H. Cimrin, E. S. Ucan, M. Gok, A. Akkoclu (Izmir, Turkey)
| |
Corticosteroid-dependent bronchial asthma: lack of a control of disease
O. E. Bogooudinova, R. S. Fassakhov (Kazan, Russia)
| |